Last checked at 13 Mar 2023 09:40
LONDON BROKER RATINGS: JPMorgan cuts BAT; raises Bunzl
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Hikma Pharmaceuticals Share News (HIK)
HIK Share
Price
HIK Share
News
HIK Share
Chat
HIK Share
Trades792
HIK
Live RNS
HIK Share
Charts
HIK Level 2
Console
HIK Live
Share Price
HIK Broker
Ratings
HIK Directors
Deals
HIK Financial
Diary
HIK
Fundamentals
HIK Short
Positions
HIK
Media
Hikma Pharmaceuticals Information
Share Price Information for Hikma Pharmaceuticals (HIK)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1,958.00
Bid:
1,963.00
Ask:
1,965.00
Change:
-36.00 (-1.81%)
Spread:
2.00 (0.102%)
Open:
2,004.00
High:
2,004.00
Low:
1,958.00
Prev. Close:
1,994.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Hikma lifts full year revenue guidance
Mon, 08th Jul 2013 07:06
Hikma Pharmaceutical said all of its businesses have continued to perform well and overall it expects revenue to grow by around 17 per cent in 2013, up from previous guidance of around 13 per cent.Across its main businesses, generics continued to benefit from strong doxycycline sales. Given the strong performance of doxycycline, Hikma said it is raising its full year guidance for this business to revenue of around $200m with a reported operating margin of above 30%. Elsewhere its branded business remains on track to meet its current full year guidance of around 9% revenue growth or 11% in constant currency, with adjusted operating margin in line with 2012. Due to the timing of shipments, Branded revenue growth is expected to be stronger in the second half of the year, Hikma explained.Its injectables business has performed well since its last update in May, driven by strong performances in the US and Europe. Hikma said there has been strong demand from the MENA region, where it has won some key tenders. "We expect these tenders will drive MENA revenue growth in the second half of the year. We continue to expect the global injectables business to deliver low double digit revenue growth for the full year," the group said in a statement.Chief Executive Officer Said Darwazah commented: "We are performing well across all of our businesses and I am pleased to be able to raise our group guidance for the full year once again.""Overall, our diversified business model is positioning the group to deliver another strong year in 2013."
More News
9 Mar 2023 09:15
LONDON BROKER RATINGS: Liberum cuts National Express to 'sell'
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:
Read more6 Mar 2023 09:48
LONDON BROKER RATINGS: DB cuts Reckitt; Jefferies likes Tesco
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:
Read more1 Mar 2023 09:52
LONDON BROKER RATINGS: Canaccord says sell Future; Investec likes RWS
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:
Read more27 Feb 2023 09:38
Berenberg raises target price on Hikma Pharmaceuticals
(Sharecast News) - Analysts at Berenberg raised their target price on drugmaker Hikma Pharmaceuticals from 1,440.0p to 1,740.0p on Monday on the back of the group's recent trading update.
Read more27 Feb 2023 09:26
LONDON BROKER RATINGS: Citi cuts Quilter to 'sell'; Goldman likes GSK
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:
Read more24 Feb 2023 09:37
LONDON BROKER RATINGS: SocGen cuts Burberry; BofA cuts WH Smith
(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:
Read more23 Feb 2023 09:54
Hikma Pharmaceuticals profit halves in 2022 on Generics impairment
(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reported a dip in annual revenue for 2022, as profit tumbled due to high inflation and adjustments regarding expectations for its Generics business.
Read more23 Feb 2023 09:02
LONDON MARKET OPEN: Mixed open in London; Rolls-Royce up, Mondi down
(Alliance News) - Stock prices in London opened mixed on Thursday, with large-cap indices underperforming amid mixed corporate earnings.
Read more23 Feb 2023 07:59
Competition in generics sees Hikma Pharmaceuticals's profits decline by a tenth
(Sharecast News) - Hikma Pharmaceuticals posted lower full-year profits as stiff competition in generics saw its top line growth flatten out.
Read more23 Feb 2023 07:56
LONDON BRIEFING: WPP profit jumps in 2022; guides for further growth
(Alliance News) - Stocks in London were called to open slightly higher on Thursday, as investors were unfazed by a fairly uneventful set of policy meeting minutes from the US central bank.
Read more22 Feb 2023 21:50
Hikma accuses Amarin of suppressing generic versions of heart pill
Hikma claims Amarin used exclusive agreements with suppliers to frustrate generic rivals
*Read more16 Feb 2023 15:49
UK earnings, trading statements calendar - next 7 days
| Friday 17 February | |
| Allianz Technology Trust PLC | Full Year Results |
| Kingspan Group PLC | Full Year Results |
| NatWest Group PLC | Full Year Results |
| Pod Point Group Holdings PLC | Full Year Results |
| Segro PLC | Full Year Results |
| Monday 20 February | |
| Bank of Cyprus Holdings PLC | Full Year Results |
| Georgia Capital PLC | Full Year Results |
| Goldplat PLC | Full Year Results (TBC) |
| LungLife AI Inc | Full Year Results |
| Tristel PLC | Half Year Results |
| Wilmington PLC | Half Year Results |
| Tuesday 21 February | |
| Antofagasta PLC | Full Year Results |
| BHP Group Ltd | Half Year Results |
| Blancco Technology Group PLC | Half Year Results |
| Finsbury Food Group PLC | Half Year Results |
| HSBC Holdings PLC | Full Year Results |
| InterContinental Hotels Group PLC | Full Year Results |
| Safestore Holdings PLC | Trading Statement |
| Smith & Nephew PLC | Full Year Results |
| Springfield Properties PLC | Half Year Results |
| Sylvania Platinum Ltd | Half Year Results |
| Trifast PLC | Trading Statement |
| Wednesday 22 February | |
| Avingtrans PLC | Half Year Results |
| City of London Investment Group PLC | Half Year Results |
| Conduit Holdings Ltd | Full Year Results |
| Liberty Global PLC | Full Year Results |
| Lloyds Banking Group PLC | Full Year Results |
| Primary Health Properties PLC | Full Year Results |
| Renewables Infrastructure Group Ltd | Full Year Results |
| Rio Tinto PLC | Full Year Results |
| Synectics PLC | Full Year Results |
| TBC Bank Group PLC | Full Year Results |
| Transense Technologies PLC | Half Year Results |
| Thursday 23 February | |
| Anglo American PLC | Full Year Results |
| Arbuthnot Banking Group PLC | Trading Statement |
| BAE Systems PLC | Full Year Results |
| Bluefield Solar Income Fund Ltd | Half Year Results |
| Drax Group PLC | Full Year Results |
| Driver Group PLC | Full Year Results |
| Genus PLC | Half Year Results |
| Hays PLC | Half Year Results |
| Hikma Pharmaceuticals PLC | Full Year Results |
| Howden Joinery Group PLC | Full Year Results |
| Macfarlane Group PLC | Full Year Results |
| Made Tech Group PLC | Half Year Results |
| Mondi PLC | Full Year Results |
| Morgan Sindall Group PLC | Full Year Results |
| Pantheon International PLC | Half Year Results |
| Rolls-Royce Holdings PLC | Full Year Results |
| Serco Group PLC | Full Year Results |
| Spectris PLC | Full Year Results |
| Versarien PLC | Full Year Results |
| WPP PLC | Full Year Results |
| Copyright 2023 Alliance News Ltd. All Rights Reserved. |
25 Jan 2023 09:33
LONDON BROKER RATINGS: Goldman likes UK banks; HSBC cuts Dr Martens
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:
Read more18 Jan 2023 15:07
Director dealings: Hikma Pharmaceuticals director snaps up shares
(Sharecast News) - Hikma Pharmaceuticals revealed on Wednesday that non-executive director Deneen Vojta had acquired 1,000 ordinary shares in the FTSE 250-listed drugmaker.
Read more